#### Note: Always consult a healthcare professional before starting any new medication or treatment regimen
Published clinical research has characterised the compound in controlled trials: a Phase 2 obesity trial reported dose-dependent body-weight change in the study population (Jastreboff et al., 2023), and a separate Phase 2 trial investigated the GIP/GLP-1/glucagon agonist in people with type 2 diabetes (Rosenstock et al., 2023)
M., von Gise, A., Zhou, P., Hu, T., He, L., Wu, K
Thats what entrepreneurs do: We build what didnt exist. Even his concept of performance has evolved
This means that the body will remove excess B12 and it cannot reach toxic levels